Urinary Tract Infection & Pyelonephritis

[1]

1. Define the syndrome before naming the organism

Do not define UTI as “bacteria in normally sterile urine.” A urinary microbiome exists, and bacteriuria can be colonisation. Diagnose UTI when symptoms or signs are attributable to infection of the urinary tract, supported by urinalysis and culture where the syndrome or risk profile makes testing useful.[3]

Asymptomatic bacteriuria (ASB) is bacteriuria, irrespective of pyuria, without symptoms attributable to UTI. Pyuria does not convert ASB into infection.[3]

Localized versus systemic disease

• Localized cystitis: acute dysuria, frequency, urgency or suprapubic discomfort without systemic features. Haematuria may occur.[1]
• Systemic UTI / pyelonephritis: fever or hypothermia, rigors, flank pain or costovertebral-angle tenderness, vomiting, hypotension, delirium with systemic illness, or other organ dysfunction. Pyelonephritis can be afebrile; no single temperature cut-off rules it in or out. These syndrome terms follow the current EAU Urological Infections guideline.[1]

A patient with bladder symptoms plus fever or instability is not “simple cystitis”; reassess for systemic infection, obstruction and a non-urinary source under the EAU Urological Infections framework.[1]

Risk factors modify probability, severity and treatment

The old rule “every man, pregnant person, older adult or person with diabetes has complicated UTI” is too blunt. Current EAU terminology first asks whether infection appears confined to the bladder or extends beyond it, then records factors that may alter pathogens, exposure, failure or source control: pregnancy; prostatic involvement; obstruction, retention, stone or reflux; catheter or instrumentation; renal impairment; diabetes or immunocompromise; transplant; recent antibiotics; and a prior resistant isolate.[1]

[3]

2. Mimics and diagnostic traps

• Vaginitis or vulvovaginal inflammation: discharge, itch, external dysuria or dyspareunia.[1]
• Urethritis / sexually transmitted infection: urethral or cervical discharge, exposure history, sterile routine culture; use appropriate NAAT.[1]
• Stone or obstruction: colicky flank-to-groin pain, haematuria, retention or hydronephrosis; fever with obstruction is an emergency.[1]
• Bladder pain syndrome: chronic pain related to filling, frequency and repeatedly negative cultures.[1]
• Prostatitis: fever, pelvic or perineal pain, obstructive symptoms and a tender prostate; avoid prostatic massage.[1]
• Other abdominal or pelvic disease: appendicitis, pelvic inflammatory disease, ectopic pregnancy, diverticulitis and malignancy require targeted examination and testing.[1]

In an older or catheterised patient, delirium, falls, cloudy or malodorous urine, pyuria or bacteriuria alone are not enough. Look for local urinary symptoms, systemic signs and alternative causes; observation rather than antibiotics is recommended when there are no attributable urinary or systemic features.[3][5]

3. How infection develops

Most bacterial infection is ascending: periurethral gut flora reach the bladder, adhere and may ascend through the ureter to renal parenchyma. Type-1 fimbriae bind uroplakin in bladder; P-fimbriae bind Galα1-4Gal receptors and are associated with upper-tract infection. Stasis, reflux, catheter biofilm, stone and obstruction weaken washout or bypass defences.[1]

E. coli predominates in community UTI, but pathogen probabilities change with recent care, instrumentation, prior antibiotics and previous isolates. Do not infer infection from candiduria or broad organism stereotypes; clinical syndrome and specimen quality remain essential.[1][5]

[1]

4. Urine collection and interpretation

Collect the right specimen

For a midstream specimen, give clear local collection instructions and collect before antibiotics when feasible. Cleansing requirements vary by protocol. For an indwelling catheter, sample aseptically from the designated sampling port, never from the drainage bag. If the catheter is replaced because it is still required, culture from the new catheter.[5]

Dipstick and microscopy

Nitrite and leucocyte esterase change probability; they do not independently decide treatment. A negative nitrite does not exclude UTI, especially with short bladder dwell time or a non-nitrate-reducing organism. Pyuria supports urinary inflammation but neither proves symptomatic UTI nor distinguishes UTI from ASB or CAUTI. Interpret every result against pretest probability and specimen quality.[3][5]

Culture

A classic low-risk localized cystitis presentation may be diagnosed clinically. Culture before treatment when feasible for systemic UTI or pyelonephritis, pregnancy, men with suspected prostatic involvement, catheter-associated symptoms, recurrence, treatment failure, recent resistant organisms or antibiotics, immunocompromise, and other risk-factor cases.[4][5]

Counts below the classical 10^5 CFU/mL threshold can be clinically significant in a symptomatic patient; interpretation depends on syndrome, sex, specimen and organism. For ASB in voided urine, the IDSA 2019 ASB guideline uses at least 10^5 CFU/mL; women formally require two consecutive specimens, while obstetric practice uses one early-pregnancy screening culture. For compatible CAUTI, the IDSA CAUTI guideline uses at least 10^3 CFU/mL of one or more bacterial species from an appropriate catheter specimen.[3][5]

5. Investigations and imaging

For systemic illness obtain renal function, blood count and inflammatory markers; add lactate, blood cultures and organ-function tests when sepsis is possible. Check pregnancy where relevant before imaging or prescribing.[6]

Imaging practice is jurisdiction- and risk-dependent. The current EAU Urological Infections guideline recommends early imaging for systemic UTI and escalation when obstruction, stone, acute kidney injury, solitary kidney, transplant, immunocompromise, high-risk diabetes, sepsis or an atypical course could change management; the UK NICE acute-pyelonephritis guideline NG111 does not require routine imaging for every improving low-risk case. Reassess and image if expected improvement has not occurred within 48 to 72 hours.[1]

Ultrasound is the first radiation-sparing test in pregnancy and often detects hydronephrosis; contrast CT is usually most informative for gas, a renal/perinephric collection or an uncertain obstruction in a nonpregnant adult. A negative ultrasound does not exclude obstruction or abscess.[1]

6. Antimicrobial stewardship framework

[11]

An effective antibiotic is active against the organism and reaches adequate urine or relevant tissue exposure. For nonseptic localized infection, follow the current regional syndrome-specific policy. For septic complicated UTI, the IDSA 2025 cUTI guideline recommends a four-step empirical assessment:[11]

1. severity and sepsis;[11]
2. patient-specific risk factors, including prior urine susceptibility results and recent antibiotic exposure;[11]
3. allergy, interactions, pregnancy, current renal function and likely relevant tissue exposure; and[10]
4. a recent local antibiogram relevant to syndrome and setting.[11]

Obtain cultures without delaying urgent care, review at 48 to 72 hours or earlier when susceptibilities return, narrow spectrum, switch IV to oral when clinically improving and able to absorb an active oral option, and count duration from the first day of effective therapy.[11]

The historical 20% trimethoprim-sulfamethoxazole and 10% fluoroquinolone resistance thresholds belong to the 2010 guideline population of premenopausal nonpregnant women without urological abnormality or major comorbidity. They are not universal thresholds for pregnancy, men, CAUTI, sepsis or current systemic UTI.[2]

Localized cystitis

Use a current regional guideline. Nitrofurantoin, trimethoprim-containing regimens, fosfomycin and pivmecillinam are not globally interchangeable: availability, resistance, pregnancy, renal thresholds, contraindications and licensed duration differ. Nitrofurantoin and oral fosfomycin do not achieve adequate renal-parenchymal exposure and must not be used for pyelonephritis.[10]

Systemic UTI / pyelonephritis

Culture all cases. Decide outpatient versus inpatient care from stability, vomiting/oral absorption, pregnancy, renal function, obstruction and reliable follow-up. Select an oral or parenteral agent from the current regional systemic-UTI guideline and prior susceptibility; narrow promptly. The EAU Urological Infections guideline and IDSA 2025 cUTI guideline are source examples, not a universal formulary.[11]

For improving adults within the populations studied by IDSA 2025, the guideline suggests 5 to 7 days for a fluoroquinolone or 7 days for a non-fluoroquinolone, counted from the first effective day. Do not extrapolate automatically to severe sepsis, complete obstruction, abscess, CKD, immunocompromise, catheterised patients, prostatitis, pregnancy or recent urological surgery; these groups were often excluded and need individualized source control and duration.[11]

Renal dosing

Check the current product label or local renal monograph for the exact drug, indication, kidney metric and route. Reassess during acute kidney injury because creatinine-based estimates lag changing function. Aminoglycosides and other concentration-monitored agents require local therapeutic-drug-monitoring protocols. “Renally adjust” must never mean reduce a time-critical loading exposure by reflex.[9][10]

7. Asymptomatic bacteriuria

The IDSA 2019 ASB guideline recommends screening and treating ASB in pregnancy and before endoscopic urological procedures associated with mucosal trauma. For the procedure, use a targeted agent and one or two doses started 30 to 60 minutes before rather than a prolonged course.[3]

Do not routinely screen or treat ASB in healthy nonpregnant adults, older adults, diabetes, spinal-cord injury, short- or long-term catheters, or elective nonurological surgery. IDSA identifies knowledge gaps in the first month after renal transplantation, high-risk neutropenia and at catheter removal; do not invent a universal rule.[3]

8. Pregnancy

The ACOG 2023 Clinical Consensus recommends one urine culture early in prenatal care. Treat culture-confirmed ASB and acute cystitis with a 5- to 7-day targeted course, with single-dose fosfomycin an exception when susceptibility and the clinical context make it appropriate. Choose from susceptibility, gestation, allergy, current renal function and the local obstetric formulary. The often-quoted 30% to 40% untreated progression comes from older studies and should not be presented as a contemporary absolute risk.[4]

There is insufficient evidence to mandate repeat screening after a negative initial culture or routine test-of-cure after treated ASB. After cystitis, ACOG permits either a repeat culture 1 to 2 weeks after treatment or symptom-triggered follow-up.[4]

Pregnancy antibiotic selection is indication-specific: confirm lower- versus upper-tract disease, use culture and susceptibility, check gestation, allergy, renal function, G6PD status when relevant, the current product label and local obstetric policy. Nitrofurantoin and fosfomycin are lower-tract options and are not appropriate for pyelonephritis; avoid phenotype-independent class rules.[4][10]

Pregnant patients with pyelonephritis should initially be managed as inpatients with culture-guided parenteral therapy, obstetric assessment and fetal monitoring appropriate to gestation. Under ACOG, complete 14 days total therapy, image promptly if obstruction or deterioration is suspected, and obtain a urine culture after treatment.[4]

9. Men and prostatitis

In men, distinguish cystitis/systemic UTI from acute bacterial prostatitis. Pelvic or perineal pain, obstructive symptoms and a tender prostate support prostatitis; obtain culture and avoid prostatic massage. Retention, sepsis or abscess requires urgent urological input under the EAU Urological Infections guideline.[1]

The UK NICE acute-prostatitis guideline NG110 advises reviewing therapy after 14 days and stopping or continuing for another 14 days according to symptoms, examination and test results. Select a prostate-penetrating agent only after contraindication, interaction, renal function, susceptibility and fluoroquinolone-safety review. Do not teach an unconditional fixed course or automatic fluoroquinolone.[10]

10. Recurrent UTI

Under NICE recurrent-UTI guideline NG112, recurrent UTI means at least two episodes in 6 months or three in 12 months. Confirm that episodes are compatible and document cultures where possible. Do not routinely image uncomplicated recurrent lower UTI, but refer or investigate recurrent upper UTI, unknown cause, men, persistent haematuria or features suggesting obstruction, stone, retention or malignancy.[1]

Discuss hydration and modifiable triggers without promising benefit from post-coital voiding or wiping direction.[1]

The NICE NG112 vaginal-oestrogen recommendation supports vaginal oestrogen after shared decision-making for peri- or postmenopausal patients when appropriate and advises against systemic hormone replacement solely to prevent UTI.[12]

Cranberry can be discussed with uncertainty about preparation, dose and population-specific benefit.[7]

The NICE NG112 methenamine-eligibility recommendation allows methenamine hippurate as an alternative to daily antibiotic prophylaxis in nonpregnant women after the current infection is treated and simpler measures, vaginal oestrogen or single-dose prophylaxis have been inadequate.[13]

The NICE NG112 interaction advice says to seek specialist advice in pregnancy, recurrent upper UTI or complicated disease and to avoid alkalinising citrate sachets while taking methenamine.[13]

The NICE NG112 methenamine-review recommendation is review at 6 months, then annually.[13]

If antibiotic prophylaxis is chosen, the NICE NG112 review recommendation is to use prior cultures and local resistance and review at least every 6 months, not prescribe automatically for a fixed 6- to 12-month course.[13]

11. Catheter-associated UTI

Diagnose CAUTI from compatible urinary or systemic features plus an appropriate culture. Pyuria, cloudy urine or odour alone do not diagnose it. Remove an unnecessary catheter; if it remains required, preserve a closed system and collect from the port.[5]

Replacement thresholds are regional. The IDSA CAUTI guideline advises replacing a catheter in place for more than 2 weeks when it is still required, then culturing the new catheter. NICE CAUTI guideline NG113 advises considering removal or change after more than 7 days, without delaying antibiotics. State which policy you use.[5]

IDSA recommends 7 days for prompt response and 10 to 14 days for delayed response, with selected shorter regimens only in defined patients. This is not a universal “7-day CAUTI” rule; source control, organism, response and host exclusions matter.[5]

12. Urosepsis, obstruction and source control

For septic shock or high-likelihood sepsis, SSC 2021 recommends locally appropriate antimicrobials immediately, ideally within 1 hour. For possible sepsis without shock, perform rapid assessment and, if concern persists, administer antibiotics within 3 hours. Do not delay urgent therapy for cultures.[6]

SSC 2021 suggests at least 30 mL/kg crystalloid within the first 3 hours for sepsis-induced hypoperfusion or shock, but this is weak, low-quality evidence: individualize and repeatedly reassess, especially with kidney or heart disease, and start vasopressor support when indicated.[6]

The EAU Urological Infections guideline treats an infected obstructed collecting system as a urological emergency. Antibiotics, resuscitation and urgent decompression by ureteric stent or percutaneous nephrostomy are parallel actions; do not wait for antibiotic “response” before drainage.[6]

13. Emphysematous disease, abscess and other complications

Emphysematous pyelonephritis is a necrotising gas-forming infection, often associated with diabetes or obstruction. The Huang-Tseng CT classes are: 1, gas in the collecting system only; 2, gas in renal parenchyma without extrarenal extension; 3A, perinephric extension; 3B, pararenal extension; and 4, bilateral disease or a solitary functioning kidney. This replaces the unsafe old “class I parenchyma/class II extension” sequence.[8]

Management combines effective antimicrobials, resuscitation, glycaemic control and urgent urology. Drain obstruction or a drainable focus; reserve nephrectomy for failed conservative/source-control management, a non-salvageable kidney or selected unstable cases. Radiological class alone does not mandate nephrectomy; the current EAU guideline favours individualized source control.[8]

A renal or perinephric abscess, papillary necrosis or pyonephrosis should be considered when pain, fever or organ dysfunction persists despite apparently effective therapy. CT and source control are central. Do not attach a universal candiduria regimen: candiduria is often colonisation and requires a separate syndrome-specific candidiasis assessment.[3]

14. Follow-up and exam-safe synthesis

• No routine post-treatment culture is needed after resolved nonpregnant uncomplicated UTI.[1]
• In pregnancy, ACOG 2023 supports evidence-limited options after treated ASB/cystitis but recommends a urine culture after pyelonephritis.[4]
• Failure to improve by 48 to 72 hours requires diagnostic, exposure, resistance and source-control reassessment under current EAU guidance.[1]
• Persistent or recurrent haematuria needs risk-based reassessment; it does not mean automatic cystoscopy for every patient.[1]

Rapid viva answer

“First I decide whether this is localized cystitis, systemic UTI/pyelonephritis, ASB or a mimic. I record pregnancy, prostate, catheter, renal function, obstruction, immune state, recent antibiotics and resistant isolates. I collect the correct culture when indicated, but never delay sepsis treatment. Empirical therapy follows the current syndrome-specific regional policy; for septic complicated UTI I also use prior susceptibility and the recent local antibiogram. I narrow and renal-adjust when susceptibilities return. Sepsis plus obstruction needs urgent drainage with antibiotics.”[11]

References

1. [1]Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden Infect Dis Clin North Am, 2014.PMID 24484571
2. [2]Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases Clin Infect Dis, 2011.PMID 21292654
3. [3]Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America Clin Infect Dis, 2019.PMID 30895288
4. [4]American College of Obstetricians and Gynecologists. Urinary Tract Infections in Pregnant Individuals Obstet Gynecol, 2023.PMID 37473414
5. [5]Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America Clin Infect Dis, 2010.PMID 20175247
6. [6]Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021 Crit Care Med, 2021.PMID 34605781
7. [7]Williams G, Hahn D, Stephens JH, et al. Cranberries for preventing urinary tract infections Cochrane Database Syst Rev, 2023.PMID 37068952
8. [8]Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis Arch Intern Med, 2000.PMID 10737279
9. [9]Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles Clin J Am Soc Nephrol, 2018.PMID 29934432
10. [10]Eyler RF, Shvets K. Clinical Pharmacology of Antibiotics Clin J Am Soc Nephrol, 2019.PMID 30862698
11. [11]Zahavi I, Kunwar D, Olchowski J, et al. Short vs. long antibiotic treatment for pyelonephritis and complicated urinary tract infections: a living systematic review and meta-analysis of randomized controlled trials Clin Microbiol Infect, 2025.PMID 40228579
12. [12]Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections N Engl J Med, 1993.PMID 8350884
13. [13]Harding C, Chadwick T, Homer T, et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT Health Technol Assess, 2022.PMID 35535708